OnlineWebFonts_Com({ 'Id':'.div', 'Data':__Animations['342960'], }).Play(); 2Use the icon class on "display:inline" elements: TAG Effective Import Iconsfree Import Animationsfree More Cost-effective Style icons cost 378 2565 cost 136 3612...
Meet Alice Barry, the Wife of 'SNL' Creator Lorne Michaels TV 'RuPaul's Drag Race' Star Crystal Envy Breaks Down Her Shocking Elimination: 'I Was Kind of Killing It' (Exclusive) Movies 'Captain America: Brave New World' Is Marvel Fatigue Personified (Review)...
The cost per ICON point reduction is a simple and effective method of comparing cost-effectiveness between orthodontic practitioners in different countries. 展开 关键词: Cost Effectiveness Reduction (chemical) EUROPEAN Cost aspects therapeutic aspects ...
doi:10.1001/jamacardio.2021.1437 editorial comment icon Editorial Comment related articles icon Related Articles Editorial Dapagliflozin Derek S. Chew, MD, MSc; Daniel B. Mark, MD, MPH JAMA Cardiology News From the JAMA Network Is Dapagliflozin Cost-effective for Treating Heart Failure? Anita Slomski...
Graphs for a particular query can be temporarily hidden by clicking the eye icon on the right side of the input field. When the eye icon is clicked while holding the ctrl key, then query results for the rest of queries become hidden except of the current query results.See the example ...
doi:10.1001/jamanetworkopen.2022.18189 related articles icon Related Articles Correction Error in Table JAMA Network Open Key Points Question Among patients with chronic obstructive pulmonary disease (COPD), is pulmonary rehabilitation (PR) after COPD hospitalization cost-effective in the US health care ...
It can become cost-effective with the ICON-7 protocol, in patients at high risk of progression using biosimilar bevacizum... 查看全部>> Darshan A Mehta,Joel W Hay 被引量: 33发表: 0年 Is FDA-Approved Bevacizumab Cost-Effective When Included in the Treatment of Platinum-Resistant Recurrent ...
Conclusions Preliminary results suggest that transitional care programs reduce 30-day readmission rates for patients with heart failure. This underscores the potential of the intervention to be effective in a real-world setting, but payment reform may be required for the intervention to be financially ...
1A). Two-way sensitivity analyses demonstrated that when the utility of PFS in the olaparib plus bevacizumab patients group was higher than 0.913 and the utility value for the bevacizumab was varied within the specified range, the olaparib plus bevacizumab will be a cost-effective treatment option...
doi:10.1001/jamainternmed.2022.5010 Key Points Question Is empagliflozin cost-effective for patients with heart failure with preserved ejection fraction (HFpEF)? Findings In this economic evaluation using a Markov model based on the EMPEROR-Preserved trial population of 5988 patients, empagliflozin had ...